# Vogenx, Inc. — capital_raise/public_offering [announced]
Source: SEC API (secapi.ai) · situation sit_b07cfa85d570b7d5a7d7 · retrieved 2026-08-11T15:54:05.883Z

## Overview
Vogenx, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia and gastroparesis, with its lead product candidate being mizagliflozin, a selective inhibitor of the sodium-glucose transporter 1 (SGLT1).

Vogenx, Inc., a clinical-stage biopharmaceutical company developing novel therapies for metabolic diseases, is conducting an initial public offering of 6,250,000 shares of common stock at an expected price between $11.00 and $13.00 per share. The company has applied to list its common stock on the Nasdaq Capital Market under the symbol "VOGX," and the closing of the offering is contingent upon such listing approval. The underwriters have been granted a 45-day option to purchase up to 937,500 additional shares at the initial public offering price, less underwriting discounts and commissions. Based on an assumed midpoint price of $12.00 per share, the company estimates net proceeds of approximately $67.8 million (or $78.2 million if the underwriters exercise their option in full), after deducting estimated underwriting discounts, commissions, and offering expenses.

## Terms
- Counterparty: Public investors · Consideration: cash · Price/share: $12

## Key dates
- Announced 2026-07-29

## Timeline
- 2026-07-29 · S-1/A (0001185185-26-003162): S-1/A - Vogenx, Inc. — *Vogenx, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia and gastroparesis, with its lead product candidate being mizagliflozin, a selective inhibitor of the sodium-glucose transporter 1 (SGLT1).* Vogenx, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for metabolic diseases including post-bariatric hypoglycemia and gastroparesis, is conducting an initial public offering of 6,250,000 shares of common stock at an expected price between $11.00 and $13.00 per share. The company has granted underwriters a 45-day option to purchase up to 937,500 additional shares at the initial public offering price, less underwriting discounts and commissions. Assuming a midpoint price of $12.00 per share, the company expects net proceeds of approximately $67.8 million (or $78.2 million if the underwriters exercise their option in full), after deducting estimated underwriting discounts and commissions and offering expenses. The company intends to use the net proceeds to fund continued development of its lead product candidate, mizagliflozin, an SGLT1 inhibitor in development for post-bariatric hypoglycemia, gastroparesis, and GIP-dependent Cushing's Syndrome, along with general corporate purposes and working capital.
  https://www.sec.gov/Archives/edgar/data/1903784/0001185185-26-003162.txt
- 2026-08-10 · S-1/A (0001185185-26-003353): S-1/A - Vogenx, Inc. — *Vogenx, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia and gastroparesis, with its lead product candidate being mizagliflozin, a selective inhibitor of the sodium-glucose transporter 1 (SGLT1).* Vogenx, Inc., a clinical-stage biopharmaceutical company developing novel therapies for metabolic diseases, is conducting an initial public offering of 6,250,000 shares of common stock at an expected price between $11.00 and $13.00 per share. The company has applied to list its common stock on the Nasdaq Capital Market under the symbol "VOGX," and the closing of the offering is contingent upon such listing approval. The underwriters have been granted a 45-day option to purchase up to 937,500 additional shares at the initial public offering price, less underwriting discounts and commissions. Based on an assumed midpoint price of $12.00 per share, the company estimates net proceeds of approximately $67.8 million (or $78.2 million if the underwriters exercise their option in full), after deducting estimated underwriting discounts, commissions, and offering expenses.
  https://www.sec.gov/Archives/edgar/data/1903784/0001185185-26-003353.txt

## Citations
- 0001185185-26-003162 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000118518526003162
- 0001185185-26-003353 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000118518526003353